US panel backs Acorda's fampridine for MS, but urges study of lower dose
15 October 2009
Sue Sutter
A US
FDA advisory panel endorsed licensing of
Acorda Therapeutics' fampridine sustained-release (proposed trade name Apriva) for the novel indication of improving walking ability in multiple sclerosis (MS) patients. However, the panel said the company should conduct post-approval studies of a lower...
Please Login to read the full article.
15 October 2009
Sue Sutter
Please Login to read the full article.
RELATED CONTENT
COMMENT
Other Informa Comment
EVENTS
26 February 2012
Vancouver Convention Centre | Vancouver, BC, Canada
28 February 2012
Pestana Chelsea Bridge Hotel London
04 March 2012
The Marriott World Center, Orlando, Florida
JOB OF THE WEEK
Promote your vacancy here
